Blood cancers

Bispecific T cell engager therapy shows promise in pre-treated DLBCL

Glofitamab, a CD20 x CD3 T-cell engaging bispecific antibody treatment,  is a promising new therapy for patients with heavily pretreated and/or highly refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL), a study led by Peter Mac researchers has shown. Findings presented at...

Glofitamab, a CD20 x CD3 T-cell engaging bispecific antibody treatment,  is a promising new therapy for patients with heavily pretreated...
Blood cancers

Myeloma – three research highlights from ASCO 2022

Genomic studies promising future targeted therapy for multiple myeloma along with clinical trials of stem cell transplantation in newly diagnosed disease and bispecific antibodies in relapsed or refractory disease were just some of the research highlights presented at the 2022...

Genomic studies promising future targeted therapy for multiple myeloma along with clinical trials of stem cell transplantation in newly diagnosed...